• Puma Biotechnology’s third-quarter 2026 net income fell 32% year over year to $6 million.
• Total revenue rose to $55.1 million, while research and development expenses climbed 15% to $18.3 million.
• Quarterly cash provided by operating activities jumped 51% to $14.6 million.
• During the quarter, Puma initiated ALISCA-Lung2, a Phase II trial evaluating alisertib with paclitaxel in advanced small cell lung cancer.
• Full-year 2026 net income guidance increased to $20 million–$22 million from $17 million–$20 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Puma Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105266638) on November 05, 2026, and is solely responsible for the information contained therein.